drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Autologous, gene-modified CAR T-cell therapy engineered to co-target CD19 and BCMA to deplete CD19+ B cells and BCMA+ plasmablasts/long-lived plasma cells, aiming to reset humoral immunity and reduce autoantibody production in lupus nephritis and IgG4-related disease.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous gene‑modified T cells expressing dual CARs targeting CD19 and BCMA selectively recognize and kill CD19+ B cells and BCMA+ plasmablasts/long‑lived plasma cells, depleting pathogenic B‑lineage compartments to reduce autoantibody production and reset humoral immunity in autoimmune disease.
drug_name
PRG-2311
nct_id_drug_ref
NCT06497361